Cardiovascular Clinical Trials in a Pandemic: Immediate Implications of Coronavirus Disease 2019

Ernest Spitzer; Ben Ren; Jasper J Brugts; Joost Daemen; Eugene McFadden; Jan Gp Tijssen; Nicolas M Van Mieghem

doi:https://doi.org/10.15420/cfr.2020.07

Cardiovascular Clinical Trials in a Pandemic: Immediate Implications of Coronavirus Disease 2019

Ernest Spitzer, Ben Ren, Jasper J Brugts, Joost Daemen, Eugene McFadden, Jan Gp Tijssen, Nicolas M Van Mieghem

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

The coronavirus disease 2019 (COVID-19) pandemic started in Wuhan, Hubei Province, China, in December 2019, and by 24 April 2020, it had affected >2.73 million people in 185 countries and caused >192,000 deaths. Despite diverse societal measures to reduce transmission of the severe acute respiratory syndrome coronavirus 2, such as implementing social distancing, quarantine, curfews and total lockdowns, its control remains challenging. Healthcare practitioners are at the frontline of defence against the virus, with increasing institutional and governmental supports. Nevertheless, new or ongoing clinical trials, not related to the disease itself, remain important for the development of new therapies, and require interactions among patients, clinicians and research personnel, which is challenging, given isolation measures. In this article, the authors summarise the acute effects and consequences of the COVID-19 pandemic on current cardiovascular trials.

Original language	English
Pages (from-to)	e09
Journal	Cardiac failure review
Volume	6
DOIs	https://doi.org/10.15420/cfr.2020.07
Publication status	Published - Mar 2020

Access to Document

https://doi.org/10.15420/cfr.2020.07

Cite this

@article{5668fa65c3364b4797635c4bb71173f8,

title = "Cardiovascular Clinical Trials in a Pandemic: Immediate Implications of Coronavirus Disease 2019",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic started in Wuhan, Hubei Province, China, in December 2019, and by 24 April 2020, it had affected >2.73 million people in 185 countries and caused >192,000 deaths. Despite diverse societal measures to reduce transmission of the severe acute respiratory syndrome coronavirus 2, such as implementing social distancing, quarantine, curfews and total lockdowns, its control remains challenging. Healthcare practitioners are at the frontline of defence against the virus, with increasing institutional and governmental supports. Nevertheless, new or ongoing clinical trials, not related to the disease itself, remain important for the development of new therapies, and require interactions among patients, clinicians and research personnel, which is challenging, given isolation measures. In this article, the authors summarise the acute effects and consequences of the COVID-19 pandemic on current cardiovascular trials.",

author = "Ernest Spitzer and Ben Ren and Brugts, {Jasper J} and Joost Daemen and Eugene McFadden and Tijssen, {Jan Gp} and {Van Mieghem}, {Nicolas M}",

note = "Copyright {\textcopyright} 2020, Radcliffe Cardiology.",

year = "2020",

month = mar,

doi = "https://doi.org/10.15420/cfr.2020.07",

language = "English",

volume = "6",

pages = "e09",

journal = "Cardiac failure review",

issn = "2057-7540",

publisher = "Radcliffe Cardiology",

}

TY - JOUR

T1 - Cardiovascular Clinical Trials in a Pandemic

T2 - Immediate Implications of Coronavirus Disease 2019

AU - Spitzer, Ernest

AU - Ren, Ben

AU - Brugts, Jasper J

AU - Daemen, Joost

AU - McFadden, Eugene

AU - Tijssen, Jan Gp

AU - Van Mieghem, Nicolas M

PY - 2020/3

Y1 - 2020/3

N2 - The coronavirus disease 2019 (COVID-19) pandemic started in Wuhan, Hubei Province, China, in December 2019, and by 24 April 2020, it had affected >2.73 million people in 185 countries and caused >192,000 deaths. Despite diverse societal measures to reduce transmission of the severe acute respiratory syndrome coronavirus 2, such as implementing social distancing, quarantine, curfews and total lockdowns, its control remains challenging. Healthcare practitioners are at the frontline of defence against the virus, with increasing institutional and governmental supports. Nevertheless, new or ongoing clinical trials, not related to the disease itself, remain important for the development of new therapies, and require interactions among patients, clinicians and research personnel, which is challenging, given isolation measures. In this article, the authors summarise the acute effects and consequences of the COVID-19 pandemic on current cardiovascular trials.

AB - The coronavirus disease 2019 (COVID-19) pandemic started in Wuhan, Hubei Province, China, in December 2019, and by 24 April 2020, it had affected >2.73 million people in 185 countries and caused >192,000 deaths. Despite diverse societal measures to reduce transmission of the severe acute respiratory syndrome coronavirus 2, such as implementing social distancing, quarantine, curfews and total lockdowns, its control remains challenging. Healthcare practitioners are at the frontline of defence against the virus, with increasing institutional and governmental supports. Nevertheless, new or ongoing clinical trials, not related to the disease itself, remain important for the development of new therapies, and require interactions among patients, clinicians and research personnel, which is challenging, given isolation measures. In this article, the authors summarise the acute effects and consequences of the COVID-19 pandemic on current cardiovascular trials.

U2 - https://doi.org/10.15420/cfr.2020.07

DO - https://doi.org/10.15420/cfr.2020.07

M3 - Review article

C2 - 32411396

SN - 2057-7540

VL - 6

SP - e09

JO - Cardiac failure review

JF - Cardiac failure review

ER -